Overview:<\/strong> Nabumetone is a prescription non-steroidal anti-inflammatory drug. Its active metabolite, 6-MNA, helps reduce pain and inflammation. This page uses a current United Kingdom film-coated tablet document. It is a generic-name information page, not confirmation that a particular brand or strength is available in every country.<\/p>\n Uses and formulation:<\/strong> The reviewed tablet is indicated for osteoarthritis and rheumatoid arthritis when anti-inflammatory and analgesic treatment is needed. The prescriber balances symptom control with stomach, cardiovascular and kidney risks and reviews the need for ongoing treatment. Tablets are taken orally, preferably with or after food. Choosing nabumetone does not remove the general risks associated with NSAIDs.<\/p>\n Safety:<\/strong> The United Kingdom document contraindicates use in the third trimester of pregnancy and in nursing mothers, as well as in severe heart, liver or kidney failure and specified ulcer, bleeding or allergic histories. From about 20 weeks of pregnancy, fetal kidney and amniotic-fluid problems are additional concerns. Black stools, vomiting blood, sudden chest or neurological symptoms, reduced urine, or a blistering rash need urgent assessment.<\/p>\n Drug interactions:<\/strong> Avoid combining NSAIDs unless specifically directed. Anticoagulants, antiplatelet agents, SSRIs, corticosteroids and alcohol may increase gastrointestinal bleeding concerns. Blood-pressure medicines and diuretics may need kidney or potassium monitoring. Lithium, methotrexate, digoxin, ciclosporin, tacrolimus and probenecid need review. Some other label cautions are based on drug-class or limited evidence rather than a dedicated trial of every pair. Do not adjust regular medicines yourself.<\/p>\n This page provides an English summary of the cited sources. Source check: Sources<\/h2>\n
\n